Zenas BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZBIO research report →
Range $32 – $55
Price Chart
About the company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
- CEO
- Leon Oliver Moulder Jr.
- IPO
- 2024
- Employees
- 167
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on ZBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.62B
- P/E
- -2.63
- PEG
- 0.03
- P/S
- 162.89
- P/B
- 8.23
- EV/EBITDA
- -3.80
- Div Yield
- 0.00%
- Gross Margin
- -656.60%
- Op Margin
- -4785.47%
- Net Margin
- -4925.53%
- ROE
- -208.91%
- ROIC
- -85.96%
Latest fiscal year · YoY change
- Revenue
- $10.00M+100.0%
- Gross Profit
- $10.00M+107.5%
- Op Income
- $-211,385,000
- Net Income
- $-377,737,000-140.6%
- EPS
- $-8.44-124.5%
- OCF Growth
- -44.0%
- FCF Growth
- -43.9%
- 52W High
- $44.60
- 52W Low
- $13.50
- 50D MA
- $28.14
- 200D MA
- $25.49
- Beta
- -1.02
- RSI (14)
- 36
- Avg Volume
- 596.65K
No earnings-call transcripts are available for ZBIO yet.
- Free Float
- 23.4%
- Shares Outstanding
- 67.82M
- Float Shares
- 15.90M
of shares held by institutions
151 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.79M | ▲ 286.19K |
| Wellington Management Group Llp | 8.09M | ▲ 6.50M |
| Sr One Capital Management, LP | 5.04M | 0 |
| Nea Management Company, LLC | 4.02M | 0 |
| Blackrock, Inc. | 3.33M | ▲ 646.49K |
| Federated Hermes, Inc. | 3.11M | ▼ 9.50K |
| Capital International Investors | 2.93M | ▲ 422.43K |
| Enavate Sciences Gp, LLC | 2.92M | ▼ 1.00M |
| Polar Capital Holdings PLC | 2.41M | ▼ 7.40K |
| Royalty Pharma Sub-Manager, LLC | 2.39M | 0 |
| Fairmount Funds Management LLC | 2.37M | ▲ 12.33K |
| State Street Corp | 1.88M | ▼ 172.47K |
Held by 261 ETFs
Biggest fund positions in ZBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 26 | InnoCare Pharma Inc. | other | 0 |
| Sep 1, 26 | Oliger Christy J. | other | 37,000 |
| Sep 1, 26 | Oliger Christy J. | other | 0 |
| Jun 15, 26 | Nunn Jason Raleigh | other | 18,500 |
| Jun 15, 26 | Lu Hongbo | other | 18,500 |
| Jun 15, 26 | MOULDER LEON O JR | other | 500,000 |
| Jun 15, 26 | ORLOFF JOHN J | other | 18,500 |
| Jun 15, 26 | von Moltke Lisa | other | 150,000 |
| Jun 15, 26 | Allen Patricia L | other | 18,500 |
| Jun 15, 26 | Boylan James P | other | 18,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZBIO coverage
Recent articles, reports, and earnings notes.
No research on ZBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZBIO report →Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 18
Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
globenewswire.com · Nov 17
Zenas BioPharma, Inc. $ZBIO Shares Acquired by Alps Advisors Inc.
defenseworld.net · Nov 11
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
globenewswire.com · Nov 9
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 5
Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) & Zenas BioPharma (NASDAQ:ZBIO)
defenseworld.net · Nov 5
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
marketbeat.com · Oct 30
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
seekingalpha.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.